Active Investments

	Aclaris Therapeutics Aclaris, started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies.
	Aerie Pharmaceuticals Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. The Company is located in Bridgewater, NJ and Research Triangle Park, NC.
	Alimera Sciences Alimera Sciences, Inc., based in Alpharetta, GA, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
	Alvine Alvine is a Phase 2 clinical company developing biologics to target autoimmune/inflammatory diseases. The company’s lead product candidate, ALV003, is a mixture of two proteases engineered to degrade gluten. Gluten is the difficult to digest protein found in wheat, rye, and barley that triggers celiac disease in genetically susceptible individuals.
	Amarin Amarin is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being launch after approval. The company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. (Nasdaq: AMRN)
	Anthera Pharmaceuticals Anthera is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. (Nasdaq: ANTH)
	Ascenta Therapeutics Ascenta is a clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta’s current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta’s lead drug candidate, AT-101) is currently in Phase 2b clinical trials.
	Auris Medical Auris Medical is a Swiss biotechnology company developing specific pharmaceutical compounds for the prevention or treatment of inner ear disorders, an area of great unmet medical need. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. The company has completed successful Phase IIb clinical trials in both tinnitus and acute hearing loss.
	Catalyst Biosciences Catalyst is a drug discovery and development company that is creating novel catalytic biopharmaceutical products based on engineered human proteases. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Catalyst is developing both natural and engineered human proteases "Alterase Therapeutics" to treat major diseases.
	Cebix Cebix is a biopharmaceutical company focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The company has recently developed a once weekly dosage form which it is currently advancing into clinical trials. Cebix has met with the FDA and reached agreement with the Agency on its development plans in diabetic neuropathy.
	Durata Therapeutics Durata is a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata’s lead product candidate, dalbavancin, is in late-stage clinical development, and the company also has two antibiotic programs in earlier-stage, preclinical research.
	First Aid Shot Therapy Based in Burlingame, California, privately held First Aid Shot Therapy(R), Inc. is focused on the development and commercialization of a comprehensive portfolio of OTC pharmaceutical products in liquid 'shot' (40ml / 1.35oz.) format. The F.A.S.T. team is comprised of consumer product executives that have been responsible for the launch and commercial success of products such as VitaminWater and Pretzel Crisps. F.A.S.T.'s products are formulated by the Company's proprietary research and development organization, F.A.S.T. Labs(tm).
	Histogenics Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility.
	Hyperion Therapeutics Hyperion is a pharmaceutical company focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. Hyperion aims to build its portfolio of products through partnership and in-licensing. Hyperion is currently focused on the development of one compound, glycerol phenybutyrate (HPN-100), for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). The compound is currently in Phase 3 studies for UCD and in Phase 2 studies for HE.
	InteKrin Therapeutics InteKrin is a clinical-stage biopharmaceutical company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. Its lead drug candidate, INT131, is currently in Phase II clinical trials for treatment of Type 2 diabetes mellitus.
	KaloBios KaloBios is a monoclonal antibody company using its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company’s multiple programs have completed multiple Phase 1 or 2 clinical trials for Pseudomonas aeruginosa infections, cystic fibrosis patients, intensive care patients on a ventilator, inflammatory conditions and hematologic malignancies. (NASDAQ:KBIO)
	Labrys Biologics Labrys Biologics is development stage biotechnology company focused on treatments for chronic migraine. Labrys lead candidate, RN-307, is an anti-CGRP monoclonal antibody for the treatment of chronic migraine, slated to enter Phase 2 clinical trials in 2013.
	Marinus Pharmaceuticals Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. The company’s lead product is a first-in-class therapy for epilepsy.
	Mirna Therapeutics Mirna is harnessing the power of tumor suppressor microRNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways. Mirna’s miRNA \"mimic pipeline\" has broad therapeutic utility in solid and hematologic cancers as well as other therapeutic areas, and provides multiple opportunities for partnering and licensing.
	Ocera Ocera is a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera is pursuing the development of AST-120 in Crohn's disease and other gastrointestinal and liver diseases including pouchitis, hepatic encephalopathy, irritable bowel syndrome and proton pump inhibitor-resistant gastroesophageal reflux disease.
	Salveo Specialty Pharmacy Salveo, a private company headquartered in Saint Petersburg, FL, was formed to create a leading specialty pharmacy organization serving patients and customers across the country. Salveo acquires, integrates and grows select specialty pharmacy organizations that share its philosophy of providing superior customer service and clinical patient care to the chronically ill population.
	SARcode Bioscience SARcode is a venture-backed biopharmaceutical company focused on the development of best-in-class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of Tcell mediated inflammatory diseases. The Company’s lead program, targets dry eye disease and, is in Phase 3.
	Sorbent Therapeutics Sorbent is a biopharmaceutical company focused on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), congestive heart failure (CHF), chronic kidney disease (CKD), and hypertension.
	TESARO TESARO is a oncology-focused biopharmaceutical company focused on improving the lives of cancer patients by developing safer and more effective therapeutics and supportive care products. TESARO was co-founded by former executives of MGI Pharma, an oncology company that was acquired in 2008 for $3.9B. (NASDAQ:TSRO)